Group 1 - Sonim Technologies, Inc. announced a public offering of 7,400,000 shares of common stock at a price of $0.75 per share, with expected gross proceeds of approximately $5.55 million [1][2] - The company intends to use the net proceeds for operations supporting its overall business strategy, working capital, and potentially for repayment and refinancing of its indebtedness [2] - Roth Capital Partners is acting as the exclusive placement agent for the offering [2] Group 2 - The offering is being conducted under a registration statement on Form S-1, which was declared effective by the SEC on June 30, 2025 [3] - A preliminary prospectus has been filed with the SEC, and electronic copies of the final prospectus will be available on the SEC's website [3] - Sonim Technologies is recognized as a leading provider of rugged mobile solutions, serving various sectors including first responders and Fortune 500 companies since 1999 [5]

Core Viewpoint - Oragenics, Inc. has announced a public offering of up to 800,000 shares of Series H Convertible Preferred Stock and Warrants, aiming to raise approximately $20 million to fund ongoing clinical trials and other corporate purposes [1][2]. Group 1: Offering Details - The offering includes 800,000 shares of Preferred Stock and Warrants to purchase an additional 800,000 shares at an exercise price of $25.00 per share [1]. - The combined public offering price for each share of Preferred Stock and accompanying Warrant is set at $25.00 [1]. - The Preferred Stock can be converted into common stock at a conversion price of $2.50 per share [1]. Group 2: Financial Proceeds and Use - Gross proceeds from the offering are expected to be approximately $20 million before deducting fees and expenses [2]. - The net proceeds will be used to fund ongoing ONP-2 concussion clinical trials, repay a $3 million bridge note, and for general corporate purposes [2]. Group 3: Placement Agent and Regulatory Compliance - Dawson James Securities, Inc. is acting as the sole placement agent for the offering [3]. - The offering is being conducted under a registration statement filed with the SEC, which became effective on June 30, 2025 [4].

Core Viewpoint - Raytech Holding Limited has announced a public offering of 25,985,000 ordinary shares priced at $0.20 per share, aiming to raise approximately $5.197 million before expenses [1][2]. Company Overview - Raytech Holding Limited is a Hong Kong-based company with over 10 years of experience in the personal care electrical appliance industry, specializing in design, sourcing, and wholesale for international brand owners [5]. - The company offers a diverse range of personal care electrical appliances, including hair styling tools, trimmers, eyelash curlers, neck care, and nail care products [5]. Offering Details - The public offering is expected to close on July 1, 2025, subject to customary closing conditions [2]. - R.F. Lafferty & Co., Inc. is acting as the sole placement agent for the offering, while Loeb & Loeb LLP and Zarif Law Group P.C. are providing legal counsel [2][3]. - The offering is conducted under a registration statement on Form F-1, which was declared effective by the U.S. Securities and Exchange Commission on June 30, 2025 [3].

Core Viewpoint - Nektar Therapeutics has announced a public offering of $100 million in common stock, pricing the shares at $23.50 each, with the offering expected to close on July 2, 2025 [1][2]. Group 1: Offering Details - Nektar is selling 4,255,320 shares in the offering, with gross proceeds anticipated to be approximately $100 million before expenses [1]. - The underwriters have a 30-day option to purchase an additional 638,298 shares at the public offering price [1]. - Jefferies and Piper Sandler are the joint bookrunning managers, with BTIG, LLC as the passive bookrunner and H.C. Wainwright & Co. as co-manager [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including research and development, clinical development, and manufacturing costs to support drug candidates [2]. Group 3: Company Overview - Nektar Therapeutics is focused on developing innovative treatments for autoimmune and chronic inflammatory diseases, with its lead product candidate being rezpegaldesleukin (REZPEG, or NKTR-358) [6]. - The company is conducting two Phase 2b clinical trials for REZPEG, targeting atopic dermatitis and alopecia areata [6]. - Nektar's pipeline includes additional candidates such as NKTR-255, an investigational IL-15 receptor agonist, and other preclinical programs [6].

Core Viewpoint - Ascent Solar Technologies, Inc. has successfully closed a public offering of 1,000,000 shares of common stock and warrants, raising a total of $2.0 million for various corporate purposes [1][2]. Group 1: Offering Details - The public offering price was set at $2.00 per share, with the same price for the accompanying warrants, which have an exercise price of $2.00 and are exercisable immediately [1]. - The offering was facilitated by H.C. Wainwright & Co. as the exclusive placement agent [2]. - The gross proceeds from the offering amounted to $2.0 million before deducting fees and expenses [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for working capital, product development activities, general administrative expenses, and other corporate purposes [2]. Group 3: Company Background - Ascent Solar Technologies is recognized for its innovative, high-performance, flexible thin-film solar panels, supported by 40 years of research and development and 15 years of manufacturing experience [5]. - The company's photovoltaic modules have been utilized in various applications, including space missions and agrivoltaic installations, showcasing their versatility and reliability [5]. - The company's research and development center and production facility are located in Thornton, Colorado [5].

Core Viewpoint - Univest Securities, LLC has successfully closed a public offering of approximately $15 million for Globavend Holdings Limited, an emerging e-commerce logistics provider [1][4]. Group 1: Offering Details - The offering consists of 21,739,130 ordinary shares or pre-funded warrants, each sold with one Series A Warrant at an initial exercise price of $0.69 and one Series B Warrant at an initial exercise price of $1.173 [2]. - The purchase price for each ordinary share and accompanying warrants is $0.69, while the pre-funded warrants are priced at $0.689 [3]. - The gross proceeds to Globavend from this offering are approximately $15 million before deducting fees and expenses [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for capital expenditures, increasing operating capacity, working capital, general corporate purposes, purchasing warehouses, and potential mergers and acquisitions [4]. Group 3: Company Overview - Globavend Holdings Limited provides end-to-end logistics solutions primarily for enterprise customers in Hong Kong, Australia, and New Zealand, facilitating B2C transactions [9]. - The company offers integrated cross-border logistics services, including parcel drop-off, consolidation, air-freight forwarding, customs clearance, and final delivery [9].

Core Viewpoint - Ascent Solar Technologies, Inc. has announced a public offering of 1,000,000 shares of common stock and warrants, aiming to raise approximately $2.0 million for various corporate purposes [1][2]. Group 1: Offering Details - The public offering price is set at $2.00 per share, with the same price for pre-funded warrants and accompanying warrants [1]. - The warrants will have an exercise price of $2.00 per share, are immediately exercisable, and will expire five years from the issuance date [1]. - The closing of the offering is anticipated around June 30, 2025, pending customary closing conditions [1]. Group 2: Financial Aspects - The expected gross proceeds from the offering are $2.0 million before deducting fees and expenses [2]. - The net proceeds will be allocated for working capital, product development, general administrative expenses, and other corporate purposes [2]. Group 3: Company Background - Ascent Solar Technologies is recognized for its innovative, high-performance, flexible thin-film solar panels, supported by 40 years of R&D and 15 years of manufacturing experience [5]. - The company's photovoltaic modules have been utilized in various applications, including space missions and commercial construction [5]. - The research and development center, along with a 5-MW production facility, is located in Thornton, Colorado [5].

Core Viewpoint - Lifeward Ltd. has successfully closed a public offering of 4,000,000 ordinary shares and accompanying warrants, raising approximately $2.6 million in gross proceeds, which will be used for commercial efforts and working capital [1][3]. Group 1: Offering Details - The public offering price was set at $0.65 per ordinary share and associated ordinary warrant, with the warrants having an exercise price of $0.65 and expiring five years from the issuance date [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for the offering [2]. - The potential additional gross proceeds from the exercise of the ordinary warrants, if fully exercised, could amount to another $2.6 million [3]. Group 2: Company Overview - Lifeward Ltd. is a leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [1]. - The company offers a range of products including the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System, focusing on rehabilitation and recovery [6]. - Founded in 2001, Lifeward operates in the United States, Israel, and Germany, with a mission to drive innovation in the field of physical rehabilitation [6].

Core Viewpoint - CorMedix Inc. plans to offer and sell $85.0 million of its common stock in an underwritten public offering, with a potential additional 15% option for underwriters [1][2] Group 1: Offering Details - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1] - RBC Capital Markets is acting as the sole bookrunner for the offering [2] - The net proceeds will be used for general corporate purposes, including working capital and research expenses [2] Group 2: Regulatory Information - The securities are being offered under a shelf registration statement filed with the SEC on May 6, 2024, and declared effective on May 22, 2024 [3] - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and available on their website [4] Group 3: Company Overview - CorMedix is focused on developing therapeutic products for life-threatening conditions, with its lead product DefenCath® approved by the FDA on November 15, 2023 [6] - DefenCath was commercially launched in inpatient settings in April 2024 and in outpatient settings in July 2024 [6] - The company plans to commence clinical studies in Total Parenteral Nutrition and Pediatric populations in 2025 [6]

Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. has announced a public offering of 20 million shares of common stock and associated warrants, aiming to raise approximately $10 million to fund research and development activities and for general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes 20,000,000 shares of common stock and Series C and D warrants, priced at $0.50 per share, with total gross proceeds expected to be around $10 million before expenses [1]. - Series C Warrants and Series D Warrants will have an exercise price of $0.50 per share, with Series C Warrants expiring in five years and Series D Warrants expiring in 12 months [2]. - The closing of the offering is anticipated on or about June 27, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to support research and development activities, working capital, and other general corporate purposes [3]. Group 3: Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [6]. - The company's pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house and protected by composition of matter patents in multiple regions [6].